Sectors & IndustriesHealthcareDrug Manufacturers - Specialty & Generic

Best Pharmaceutical Stocks to Buy Now (2024)

Top pharmaceutical stocks in 2024 ranked by overall Zen Score. See the best pharmaceutical stocks to buy now, according to analyst forecasts for the drug manufacturers - specialty & generic industry.

According to Zen Score, the 3 best pharma stocks to buy right now are:

Neurocrine Biosciences (NASDAQ:NBIX) is the top pharmaceutical stock with a Zen Score of 64, which is 39 points higher than the pharmaceutical industry average of 25. It passed 21 out of 33 due diligence checks and has strong fundamentals. Neurocrine Biosciences has seen its stock return 34.19% over the past year, overperforming other pharmaceutical stocks by 45 percentage points.

Neurocrine Biosciences has an average 1 year price target of $144.65, an upside of 4.09% from Neurocrine Biosciences's current stock price of $138.97.

Neurocrine Biosciences stock has a consensus Buy recommendation according to Wall Street analysts. Of the 17 analysts covering Neurocrine Biosciences, 47.06% have issued a Strong Buy rating, 23.53% have issued a Buy, 29.41% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Siga Technologies (NASDAQ:SIGA) is the second best pharmaceutical stock with a Zen Score of 58, which is 33 points higher than the pharmaceutical industry average of 25. It passed 21 out of 38 due diligence checks and has strong fundamentals. Siga Technologies has seen its stock return 51.93% over the past year, overperforming other pharmaceutical stocks by 62 percentage points.

Kamada (NASDAQ:KMDA) is the third best pharmaceutical stock with a Zen Score of 57, which is 32 points higher than the pharmaceutical industry average of 25. It passed 18 out of 33 due diligence checks and has strong fundamentals. Kamada has seen its stock return 14.86% over the past year, overperforming other pharmaceutical stocks by 25 percentage points.

Kamada has an average 1 year price target of $11.00, an upside of 112.36% from Kamada's current stock price of $5.18.

Kamada stock has a consensus Buy recommendation according to Wall Street analysts. Of the 1 analyst covering Kamada, 0% have issued a Strong Buy rating, 100% have issued a Buy, 0% have issued a hold, while 0% have issued a Sell rating, and 0% have issued a Strong Sell.

Out of 6 pharmaceutical stocks that have issued dividends in the past year, the 3 pharmaceutical stocks with the highest dividend yields are:

Siga Technologies (NASDAQ:SIGA) has an annual dividend yield of 12.12%, which is 9 percentage points higher than the pharmaceutical industry average of 3.61%.

Siga Technologies's dividend payout ratio of 47.4% indicates that its high dividend yield is sustainable for the long-term.

Alkermes (NASDAQ:ALKS) has an annual dividend yield of 4.34%, which is 1 percentage points higher than the pharmaceutical industry average of 3.61%.

Alkermes's dividend payout ratio of 50% indicates that its dividend yield is sustainable for the long-term.

Phibro Animal Health (NASDAQ:PAHC) has an annual dividend yield of 3.82%, which is the same as the pharmaceutical industry average of 3.61%. Phibro Animal Health's dividend payout is stable, having never dropped by more than 10% in the last 10 years. Phibro Animal Health's dividend has shown consistent growth over the last 10 years.

Phibro Animal Health's dividend payout ratio of 129.7% indicates that its dividend yield might not be sustainable for the long-term.

Pharmaceutical stocks were down -0.67% in the last day, and up 0.64% over the last week. Evotec Se was the among the top losers in the drug manufacturers - specialty & generic industry, dropping -31.63% yesterday.

Evotec shares are trading lower. The company reported FY23 financial results.

Based on WallStreetZen's Valuation Score, the 3 most undervalued pharmaceutical stocks right now are:

Pacira Biosciences (NASDAQ:PCRX) is the most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Pacira Biosciences has a valuation score of 86, which is 67 points higher than the pharmaceutical industry average of 19. It passed 6 out of 7 valuation due diligence checks.

Pacira Biosciences's stock has dropped -43.43% in the past year. It has underperformed other stocks in the pharmaceutical industry by -33 percentage points.

Collegium Pharmaceutical (NASDAQ:COLL) is the second most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Collegium Pharmaceutical has a valuation score of 86, which is 67 points higher than the pharmaceutical industry average of 19. It passed 6 out of 7 valuation due diligence checks.

Collegium Pharmaceutical's stock has gained 51.62% in the past year. It has overperformed other stocks in the pharmaceutical industry by 62 percentage points.

Kamada (NASDAQ:KMDA) is the third most undervalued pharmaceutical stock based on WallStreetZen's Valuation Score. Kamada has a valuation score of 71, which is 52 points higher than the pharmaceutical industry average of 19. It passed 5 out of 7 valuation due diligence checks.

Kamada's stock has gained 14.86% in the past year. It has overperformed other stocks in the pharmaceutical industry by 25 percentage points.